Case series of four-factor prothrombin complex concentrate for XXXX reversal before heart transplantation.

@entity1 @entity548 @entity882 @entity56 @entity1031 @entity1229
OBJECTIVE: Describe the experience of using 4-factor prothrombin complex concentrate (PCC4) in @entity1 with a ventricular assist device (VAD) scheduled for imminent heart transplant who are receiving @entity1229 . METHODS: We are reporting a clinical case series describing 4 @entity1 with VADs treated with PCC4 for anticoagulation reversal before heart transplantation. Data collection was performed via retrospective medical chart review from March 27, 2014, to July 20,  2014. RESULTS: Average time to anticoagulation reversal was 2.45 hours and average volume of PCC4 injection was 86 mL. No @entity1 experienced a @entity1031 event or a decrease in hemoglobin indicative of a @entity548 event. Average volume of packed red blood cells, platelets, and fresh frozen plasma (FFP) @entity1 received was 2,325 mL. @entity1 1 experienced a @entity56 and @entity1 2 experienced @entity882 postoperatively. The average acquisition cost was  3,824 and the average retail price was  7,143 per complete dose. CONCLUSIONS: PCC4 contributed to efficient reduction of International Normalized Ratio (INR) before surgery. PCC4 requires less volume than FFP for similar INR reductions. PCC4 was a beneficial agent in our @entity1 with VADs; however, a cost-benefit analysis is needed to evaluate the future utility of PCC4.
